We are monitoring the litigation involving Byetta and other incretin mimetic diabetes drugs with great interest.
New York, NY (PRWEB) November 11, 2014
Plaintiffs pursuing Byetta lawsuits (http://www.byettalawsuit2013.com/) and other product liability claims involving the incretin mimetics class of Type 2 diabetes medications have asked a federal judge to reconsider his decision barring the discovery of certain information pertaining to adverse events reported to the U.S. Food & Drug Administration (FDA). In court papers filed in the U.S. District Court, Southern District of California on November 3rd, plaintiffs’ attorneys argued that an earlier decision relied on old case law. The Court has ordered defendants to file a response by December 1, 2014. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)
“We are monitoring the litigation involving Byetta and other incretin mimetic diabetes drugs with great interest, as we have been contacted by a number of patients who allegedly developed pancreatic cancer, pancreatitis and thyroid cancer due to these medications,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Byetta lawsuit evaluations to patients who may have been harmed by this drug.
Byetta Lawsuit Allegations
According to court documents, more than 540 lawsuits have been filed in the Southern District of California on behalf of individuals who allegedly developed pancreatitis due to their use of Byetta, Januvia or Victoza. All of the complaints allege that the drugs’ manufacturers failed to warn doctors and patients about their potentially harmful effects on the pancreas, as well as their alleged association with an increased risk of pancreatic cancer.
Court records indicate that a number of Byetta lawsuits involving similar allegations have been consolidated in a state-level litigation underway in California Superior Court. (In re: Byetta Cases, JCCP No. 4574) AstraZeneca, the manufacturer of the drug, also disclosed in July that it had settled more than 80 claim involving the medication.*
Byetta lawsuits and other product liability claims involving this class of medications have been mounting in U.S. courts since March 2013, when the U.S. Food & Drug Administration (FDA) announced it was reviewing findings from an unpublished study that indicated their use could be associated with precancerous changes in the cells of the pancreas.
Though the agency has been unable to conclude that such a link exists, its review is ongoing.
Individuals who developed pancreatic cancer, pancreatitis or thyroid cancer, allegedly due to their use of Byetta or another incretin mimetic may be entitled to compensation for their injury-related damages. To learn more about filing a Byetta lawsuit, please visit Bernstein Liebhard LLP’s website. For a free legal review, please call 800-511-5092.
*http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2=MDT-Type&blobheadervalue1=inline%3B+filename%3DPress-release.pdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey=id&blobtable=MungoBlobs&blobwhere=1285677813451&ssbinary=true, AstraZeneca PLC, July 31, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter
Felecia L. Stern, Esq.
Bernstein Liebhard LLP